News

Pulmonology Advisor9h
LTOT Linked to Fewer Exacerbations, Hospitalizations in COPD, ILD, and PH
Long-term oxygen therapy (LTOT) is linked to reduced exacerbations and hospitalizations in COPD, ILD, and pulmonary hypertension.
Medscape13h
Newly Approved Mepolizumab Mitigates COPD Exacerbations
Mepolizumab, a humanized monoclonal antibody that targets interleukin-5 (IL-5), significantly reduced COPD exacerbations in ...
Health and Me on MSN3d
FDA Greenlights Nucala as New Treatment for COPD
FDA approves Nucala as add-on therapy for COPD with high eosinophils, offering new hope by reducing flare-ups in patients ...
MedPage Today4d
FDA Approves Mepolizumab for COPD
Mepolizumab has had a bumpy road to arriving at its indication in COPD. An FDA advisory committee in 2018 declined to ...
Healio4d
FDA approves mepolizumab for COPD with eosinophilic phenotype
The FDA granted approval to mepolizumab for treating adults with inadequately controlled COPD and an eosinophilic phenotype, ...
Contract Pharma4d
FDA Greenlights GSK’s Nucala for Eosinophilic COPD
The FDA has granted approval to GSK's Nucala as an add-on maintenance treatment for adult patients suffering from inadequately controlled COPD.
BioSpace4d
GSK Wins COPD Expansion for Nucala After FDA Delay
The approval tees GSK up to challenge Sanofi and Regeneron, which in September 2024 won the first biologic approval for COPD ...
The American Journal of Managed Care6d
Mepolizumab Reduces COPD Exacerbations in Patients With Eosinophilic Inflammation
New findings from the MATINEE and COPD-HELP studies suggest mepolizumab could reduce exacerbations and improve quality of ...